The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-14. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Overview == Adjuvants in immunology are often used to modify or augment the effects of a vaccine by stimulating the immune system to respond to the vaccine more vigorously, and thus providing increased immunity to a particular disease. Adjuvants accomplish this task by mimicking specific sets of evolutionarily conserved molecules, so called pathogen-associated molecular patterns, which include liposomes, lipopolysaccharide, molecular cages for antigens, components of bacterial cell walls, and endocytosed nucleic acids such as RNA, double-stranded RNA, single-stranded DNA, and unmethylated CpG dinucleotide-containing DNA. Because immune systems have evolved to recognize these specific antigenic moieties, the presence of an adjuvant in conjunction with the vaccine can greatly increase the innate immune response to the antigen by augmenting the activities of dendritic cells, lymphocytes, and macrophages by mimicking a natural infection.
=== Clinical trials === The phase 1 clinical pharmacology trial described by Nishimura and colleagues evaluated insulin icodec in people with type 2 diabetes using a randomized, double-blind, double-dummy, active-controlled, multiple-dose, dose-escalation design. The study reported a mean half-life of 196 hours and glucose-lowering activity distributed across the weekly dosing interval, supporting further development as a once-weekly basal insulin. In ONWARDS 1, once-weekly insulin icodec was compared with once-daily insulin glargine U100 in adults with type 2 diabetes who had not previously used insulin. Insulin icodec was non-inferior, and statistically superior for reduction in glycated hemoglobin. The phase III ONWARDS clinical trial program evaluated once-weekly insulin icodec in adults with diabetes. ONWARDS 3 compared weekly icodec with daily insulin degludec in insulin-naïve adults with type 2 diabetes. Icodec produced a greater reduction in glycated hemoglobin after 26 weeks, with low absolute rates of clinically significant or severe hypoglycemia in both groups. ONWARDS 6 studied insulin icodec in adults with type 1 diabetes using a basal-bolus insulin regimen. Icodec was non-inferior to once-daily insulin degludec for reduction in glycated hemoglobin, but was associated with a higher rate of clinically significant or severe hypoglycemia.
Many teleosts form shoals, which serve multiple purposes in different species. Schooling is sometimes an antipredator adaptation, offering improved vigilance against predators. It is often more efficient to gather food by working as a group, and individual fish optimise their strategies by choosing to join or leave a shoal. When a predator has been noticed, prey fish respond defensively, resulting in collective shoal behaviours such as synchronised movements. Responses do not consist only of attempting to hide or flee; antipredator tactics include for example scattering and reassembling. Fish also aggregate in shoals to spawn.
Fox Islands (the main islands are Unimak, Akutan, Unalaska and Umnak) Islands of Four Mountains (the main islands are Yunaska and Chuginadak) Andreanof Islands (the main islands are Adak, Atka, Amlia, Seguam, Kanaga and Tanaga) Rat Islands (the main islands are Kiska and Amchitka) Near Islands (the main islands are Attu Island, Agattu Island and the Semichi Islands - Alaid, Nizki and Shemya) Commander Islands (the main islands are Bering and Medny) All six are located between 51° and 55° N latitude and 172° E and 163° W longitude. The largest islands in the Aleutians are Attu, and Unalaska, Umnak, and Unimak in the Fox Islands. The largest of those is Unimak Island, with an area of 1,571.41 mi2 (4,069.9 km2), followed by Unalaska Island, the only other Aleutian Island with an area over 1,000 square miles (2,600 km2). The axis of the archipelago near the mainland of Alaska has a southwest trend, but at Tanaga Island (about 178° W) its direction changes to the northwest. This change of direction corresponds to a curve in the line of volcanic fissures that have contributed their products to the building of the islands. Such curved chains are repeated about the Pacific Ocean in the Kuril Islands, the Japanese chain, and in the Philippines. All these island arcs are at the edge of the Pacific Plate and experience much seismic activity, but are still habitable; the Aleutians lie between the Pacific and North American tectonic plates. The general elevation is greatest in the eastern islands and least in the western.
=== November 2005 === -173 detainees found in an Iraqi government bunker in Baghdad were found starved, beaten and tortured. -Colin Powell's former Chief of Staff, Colonel Lawrence Wilkerson, stated in an interview with Amy Goodman on November 22 that:
Sources: en.wikipedia.org
regulating the constriction and dilation of blood vessels stimulating platelet aggregation binds to thromboxane receptor on platelets' cell membranes to trigger platelet migration and adhesion to other platelets Effects of aspirin on prostaglandin H2:
Aprataxin is 342 amino acids long and consists of FHA domain and HIT-ZnF catalyc core. It works by binding to adenylated DNA and removing AMP by catalytic side. Aprataxin is localised in the nucleus and mitochondria, which means aprataxin participates in mitochondrial DNA repair. This protein participates in base excision repair (BER) by returning abortive DNA ligation into scheduled repair by DNA polymerase beta, which would remove 5'-deoxyribosephosphate residue (dRP) and fill the gap; consequently, DNA ligase III-XRCC1 complex would seal the gap; consequently this mechanism is hampered in AOA1. Also, it might participate in microhomology-mediated end joining (MMEJ) by associating with XRCC1 and DNA ligase III and safeguarding DNA from abortive ligations by DNA ligase I, which might, again, be hampered in AOA1. iPSC with AOA1-associated mutation showed hindered differentiation into neurons which could be responsinble for early onset. Additionally, these neurons showed increased levels of cleaved PARP1 and decreased levels of APEX1. Due to the unique structure of chromatin in Purkinje cells, DNA damage (caused by aprataxin dysfunction) would hamper RNA polymerase II function, which would lead to improper splicing of some genes (such as: ITPR1, GRID2, CA8) and consequeent formation of R-loops; R-loops can exacerbate DNA damage. Because of dysregulation of genes, this would lead to ataxia. Decreased levels of albumin and elevated alpha-fetoprotein in AOA1 might be caused by transcriptional dysregulation in the liver.
=== Continued hostilities (30 May – present) === On 30 May 2026, five TTP militants were killed in combat in Darra Adamkhel in a military operation and in the same operation, eight more insurgents including two Afghan Tariq Gidar group affiliates were killed, the following day. Insurgents attacked a police station in Wana. On 1 June 2026, four TTP militants were killed during an attempted VBIED suicide attack on a military post near Miranshah. Two civilians were injured in a mortar attack in Salarzai Tehsil. Pakistani forces start "Operation Iron Fist-3" in Miranshah. From 1-3 June 2026, Pakistani forces cleared the villages of Nadeem Kot and Khuzai from TTP control, killing eight insurgents and wounding 14 to 16 under Operation Iron Fist-3 in Miranshah. On 3 June 2026, allegedly Pakistan-linked hacking group "SideCopy" conducted a cyberattack against Taliban Finance Ministry, provincial financial and revenue offices, Pashto-speaking officials and local government employees. On 4 June 2026, ISPR claimed that Pakistani forces had killed two TTP militants in Dera Ismail Khan District and two more in Sheikh Banda area of Mohmand District. Pakistani forces began the second phase of Operation Iron Fist-3 in Miranshah. Taliban and Pakistan held an informal talk in Termez, mediated by Uzbekistan. On 5 June 2026, Pakistan reiterated that it has the "right" to strike militant targets inside Afghanistan. Two sons of a tribal leader were killed in Wana. On 6 June 2026, ISPR stated that Pakistani forces had killed 27 TTP insurgents in and around Miranshah, over the last three days.
In clitoridectomy, the clitoris may be removed as part of a radical vulvectomy to treat cancer such as vulvar intraepithelial neoplasia; however, modern treatments favor more conservative approaches, as invasive surgery can have psychosexual consequences. Clitoridectomy more often involves parts of the clitoris being partially or completely removed during FGM, which may be additionally known as female circumcision or female genital cutting (FGC). Removing the glans does not mean that the whole structure is lost, since the clitoris reaches deep into the genitals. In reduction clitoroplasty, a common intersex surgery, the glans is preserved and parts of the erectile bodies are excised. Problems with this technique include loss of sensation, loss of sexual function, and sloughing of the glans. One way to preserve the clitoris with its innervations and function is to imbricate and bury the glans; however, Şenaylı et al. state that "pain during stimulus because of trapped tissue under the scarring is nearly routine. In another method, 50 percent of the ventral clitoris is removed through the level base of the clitoral shaft, and it is reported that good sensation and clitoral function are observed in follow-up"; additionally, it has "been reported that the complications are from the same as those in the older procedures for this method".
Sources: en.wikipedia.org
On 30 November, the National Guard claimed a "coup d'état" by Raed al-Matni and Assem Abo Fakhr, where they were arrested together with people related to Syrian government forces, Sources indicated that the incident was an attempted assault on the government building and police headquarters, carried out by "Gandhi Abo Fakhr and a group affiliated with him, in coordination with Suleiman Abdul Baqi, with the aim of "overthrowing al-Sheikh al-Hijri".
Klaus Biemann (November 2, 1926 – June 2, 2016) was an Austrian-American professor of chemistry at the Massachusetts Institute of Technology. His work centered on structural analysis in organic and biochemistry. He has been called the "father of organic mass spectrometry" but was particularly noted for his role in advancing protein sequencing with tandem mass spectrometry following pioneering work conducted in this area by Michael Barber.
==== Adverse effects ==== The common side effects associated with the use of Dronabinol are diverse but generally mild. They generally resolved in a few days. Common side effects include dizziness, dry mouth and headache. Others are related to an alteration of mental state, such as euphoria, mood changes, anxiety, drowsiness and abnormal thinking. Yet, impairment of cognitive performance, including memory and alertness, is not reported. The incidence of side effects may be reduced with a delayed dosing to near bedtime. Dose reduction should be considered in patients with continual side effects.
== Impact == The American Society of Health-System Pharmacists (ASHP) reported that 323 "active medication shortages" were reported in January–March 2024. As a result of drug scarcity, many healthcare systems were forced to either ration out essential drugs, triage patients based on the severity of their condition and their need for the drug, or both. Most of the medications impacted by the shortage were generic, low-cost drugs with sterile injectable medications such as chemotherapy agents being the most impacted. Tornado damage to a pharmaceutical manufacturing plant responsible for a large amount of national injectable drug production exacerbated shortages.
==== Mechanism ==== Number of chiral environments are created within the polymer. Cavities are formed between adjacent glucose units, and spaces/channels between polysaccharide chains. These chiral cavities or channels give the chiral discrimination capability to polysaccharide CSPs. The mechanism of Chiral discrimination is not well understood but believed to involve hydrogen bonding and dipole-dipole interaction between the analyte molecule and the ester or carbamate linkage of the CSP.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.